A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer [RNA-Seq]
RNA-seq (gene expression) · mouse · 43 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 43 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancerbioRxiv : the preprint server for biology · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE271053_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1129506 and SRA study SRP516823. Searching any of these in the dataset finder brings you back here.
The grouping that defines any comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Sample titles run CMZ101 … CMZ357 and carry no group information.
- GSM8367817 CMZ101
- GSM8367818 CMZ103
- GSM8367819 CMZ104
- GSM8367820 CMZ105
- GSM8367821 CMZ106
- GSM8367822 CMZ107
- GSM8367823 CMZ108
- GSM8367824 CMZ109
- GSM8367825 CMZ110
- GSM8367826 CMZ111
- GSM8367827 CMZ181
- GSM8367828 CMZ182
- GSM8367829 CMZ183
- GSM8367830 CMZ184
- GSM8367831 CMZ327
- GSM8367832 CMZ328
- GSM8367833 CMZ329
- GSM8367834 CMZ330
- GSM8367835 CMZ331
- GSM8367836 CMZ332
- GSM8367837 CMZ333
- GSM8367838 CMZ334
- GSM8367839 CMZ335
- GSM8367840 CMZ336
- GSM8367841 CMZ337
- GSM8367842 CMZ338
- GSM8367843 CMZ339
- GSM8367844 CMZ340
- GSM8367845 CMZ341
- GSM8367846 CMZ342
- GSM8367847 CMZ344
- GSM8367848 CMZ345
- GSM8367849 CMZ346
- GSM8367850 CMZ347
- GSM8367851 CMZ348
- GSM8367852 CMZ349
- GSM8367853 CMZ350
- GSM8367854 CMZ352
- GSM8367855 CMZ353
- GSM8367856 CMZ354
+ 3 more — browse all 43 samples with per-sample file links →
- GSE271066 A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer. 44 samples shares sirtuin1, neuroendocrine, identifies, prostate, forward, genetic, screen
- GSE277171 A forward genetic screen identifies potassium channel essentiality in SHH medulloblastoma maintenance [RNA-seq] 70 samples shares identifies, forward, genetic, rna-seq, screen
- GSE293874 Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity [mouse bulk RNA-seq] 167 samples shares identifies, rna-seq, screen
- GSE334845 Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors [RNA-Seq] 86 samples shares identifies, rna-seq, screen
- GSE245838 Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity [mouse scRNA-seq] 21 samples shares identifies, rna-seq, screen
- GSE227108 Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells (scRNA-seq) 18 samples shares prostate, genetic, rna-seq
- GSE296986 EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer. [scRNA-seq] 17 samples shares neuroendocrine, prostate, rna-seq
- GSE302791 Targeted CRISPR-Cas9 screening identifies core transcription factors controlling murine haemato-endothelial fate commitment [RNA-seq] 12 samples shares identifies, rna-seq, screen
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.